The Multiple Sclerosis Functional Composite A clinically meaningful measure of disability

被引:118
|
作者
Polman, Chris H. [1 ]
Rudick, Richard A. [2 ]
机构
[1] Vrije Univ Amsterdam Med Ctr, Free Univ Hosp, Dept Neurol, NL-1007 MB Amsterdam, Netherlands
[2] Cleveland Clin, Mellen Ctr Multiple Sclerosis Treatment & Res, Cleveland, OH 44106 USA
关键词
MAGNETIZATION-TRANSFER RATIO; APPEARING WHITE-MATTER; QUALITY-OF-LIFE; REFERENCE POPULATION; OUTCOMES ASSESSMENT; INTERFERON BETA-1A; STATUS SCALE; MS; PROGRESSION; GREY;
D O I
10.1212/WNL.0b013e3181dbb571
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: The Multiple Sclerosis Functional Composite (MSFC) provides a focused and sensitive evaluation of disability in patients with multiple sclerosis ( MS) that may be more responsive to change than that provided by the Expanded Disability Status Scale. Expert Clinical Opinion: The MSFC is a 3-part quantitative instrument that measures arm, leg, and cognitive function with the 9-Hole Peg Test (arm/hand dexterity), the Timed 25-Foot Walk ( leg function), and the Paced Auditory Serial Addition Test (3-second version, PASAT3; cognition). The MSFC has excellent test-retest reliability. Construct validity was supported by expected differences in scores between patients with primary or secondary progressive MS compared with relapsing-remitting MS. Concurrent validity was demonstrated by significant correlations with the Expanded Disability Status Scale, the Sickness Impact Profile, and the Short Form-36, particularly on the physical components of the latter 2 scales. MSFC scores also correlate with MRI changes. Limitations of the MSFC include practice effects with the PASAT and to a lesser extent the 9-Hole Peg Test, variations in the reference populations used to calculate Z-scores, and the lack of an accepted definition of a clinically meaningful change. Future Directions: Future research should be directed at adding a test that measures visual function ( e. g., contrast acuity), at replacing the PASAT by a cognition test that has better measurement characteristics, and at developing methods to better understand the clinical relevance of changes in MSFC scores. NEUROLOGY 2010; 74(Suppl 3): S8-S15
引用
收藏
页码:S8 / S15
页数:8
相关论文
共 50 条
  • [1] Assessing disability progression with the Multiple Sclerosis Functional Composite
    Rudick, R. A.
    Polman, C. H.
    Cohen, J. A.
    Walton, M. K.
    Miller, A. E.
    Confavreux, C.
    Lublin, F. D.
    Hutchinson, M.
    O'Connor, P. W.
    Schwid, S. R.
    Balcer, L. J.
    Lynn, F.
    Panzara, M. A.
    Sandrock, A. W.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2009, 15 (08) : 984 - 997
  • [2] The Multiple Sclerosis Functional Composite: a new clinical outcome measure for multiple sclerosis
    Rudick, RA
    Cutter, G
    Reinold, S
    [J]. MULTIPLE SCLEROSIS, 2002, 8 (05): : 359 - 365
  • [3] The Performance Scales disability measure for multiple sclerosis: use and sensitivity to clinically important differences
    Carolyn E. Schwartz
    Victoria E. Powell
    [J]. Health and Quality of Life Outcomes, 15
  • [4] The Performance Scales disability measure for multiple sclerosis: use and sensitivity to clinically important differences
    Schwartz, Carolyn E.
    Powell, Victoria E.
    [J]. HEALTH AND QUALITY OF LIFE OUTCOMES, 2017, 15
  • [5] Correlation of immunopathological patterns with multiple sclerosis functional composite disability in biopsy: confirmed multiple sclerosis
    Kale, N.
    Koenig, F. B.
    Bruck, W.
    Lassmann, H.
    Mandrekar, J. N.
    Thomsen, K.
    Weigand, S.
    Linbo, L.
    Lucchinetti, C. F.
    [J]. MULTIPLE SCLEROSIS, 2007, 13 : S139 - S140
  • [6] Measuring sustained disability progression using the multiple sclerosis functional composite
    Hutchinson, M.
    Polman, C. H.
    Rudick, R. A.
    Balcer, L. J.
    Cohen, J. A.
    Confavreux, C.
    Lublin, F. D.
    Miller, A.
    O'Connor, P. W.
    Schwid, S. R.
    Lynn, F.
    Panzara, M. A.
    Sandrock, A. W.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2007, 14 : 21 - 21
  • [7] Use of the Multiple Sclerosis Functional Composite to predict disability in relapsing MS
    Rudick, RA
    Cutter, G
    Baier, M
    Fisher, E
    Dougherty, D
    Weinstock-Guttman, B
    Mass, MK
    Miller, D
    Simonian, NA
    [J]. NEUROLOGY, 2001, 56 (10) : 1324 - 1330
  • [8] Multiple Sclerosis Functional Composite Measure (MSFC) standardized in Brazilian population
    Tilbery, CP
    Mendes, MF
    Thomaz, RB
    de Oliveira, BES
    Kelian, GLR
    Busch, R
    Miranda, PPC
    Caleffi, P
    [J]. ARQUIVOS DE NEURO-PSIQUIATRIA, 2005, 63 (01) : 127 - 132
  • [9] Development of a multiple sclerosis functional composite as a clinical trial outcome measure
    Cutter, GR
    Baier, ML
    Rudick, RA
    Cookfair, DL
    Fischer, JS
    Petkau, J
    Syndulko, K
    Weinshenker, BG
    Antel, JP
    Confavreux, C
    Ellison, GW
    Lublin, F
    Miller, AE
    Rao, SM
    Reingold, S
    Thompson, A
    Willoughby, E
    [J]. BRAIN, 1999, 122 : 871 - 882
  • [10] Disability Measure in Mexican Multiple Sclerosis Patients
    Garcia-Bermudez, R. J.
    Bertado-Cortes, B.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (1_SUPPL) : 29 - 29